Literature DB >> 8408514

Repeated aspiration of ovarian follicles and early corpus luteum cysts in an in-vitro fertilization programme reduces the risk of ovarian hyperstimulation syndrome in high responders.

A Amit1, Y Yaron, I Yovel, M R Peyser, M P David, A Botchan, J B Lessing.   

Abstract

A retrospective analysis of ovarian hyperstimulation syndrome in high responders undergoing in-vitro fertilization (IVF) is presented. High responders were defined as having > 20 follicles and serum oestradiol > 3000 pg/ml after treatment with human menopausal gonadotrophin. Of the initial 30 IVF cycles in high responders, 23 developed a moderate-to-severe ovarian hyperstimulation syndrome (76.7%). Subsequently, 15 other IVF cycles in high responders were combined with a repeated aspiration of ovarian follicles and corpus luteum cysts just prior to embryo transfer. Only three patients (20%) developed a moderate ovarian hyperstimulation syndrome (P = 0.0004). We conclude that repeated follicular aspiration is safe and results in a significant reduction in the incidence and severity of this condition in high responders undergoing IVF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408514     DOI: 10.1093/oxfordjournals.humrep.a138225

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

1.  Prevention of ovarian hyperstimulation syndrome by early aspiration of small follicles in hyper-responsive patients with polycystic ovaries during assisted reproductive treatment cycles.

Authors:  Oluseye A Oyawoye; Bina Chander; Jocelyn Hunter; Ahmed Abdel Gadir
Journal:  MedGenMed       Date:  2005-08-16

2.  Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome.

Authors:  T Tomazevic; H Meden-Vrtovec
Journal:  J Assist Reprod Genet       Date:  1996-04       Impact factor: 3.412

3.  Follicular aspiration versus coasting for ovarian hyper-stimulation syndrome prevention.

Authors:  Nayla J Bushaqer; Nawal M Dayoub; Khalsa K AlHattali; Hisham A Ayyoub; Samaher S AlFaraj; Samar N Hassan
Journal:  Saudi Med J       Date:  2018-03       Impact factor: 1.484

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.